Targeted near infrared hyperthermia combined with immune stimulation for optimized therapeutic efficacy in thyroid cancer treatment

Oncotarget
Le ZhouHui Sun

Abstract

Treatment of thyroid cancer has incurred much focus because of its high prevalency. As a new strategy treating thyroid cancer, hyperthermia takes several advantages compared with surgery or chemotherapy, including minimal invasion, low systematic toxicity and the ability to enhance the immunogenicity of cancer cells with the expression Hsp70 which serves as Toll-like receptors-4 (TLR-4 agonist). However, Hsp70 as a molecular chaperone can protect cells from heat induced apoptosis and therefore compromise the tumor killing effect of hyperthermia. In this study, to solve this problem, a combined hyperthermia therapy was employed to treat thyroid cancer. We prepared a probe with the tumor targeting agent AG to monitor thyroid tumor issue and generate heat to kill tumor cells in vivo. At the same time Quercetin (inhibitor of HSP70) and lipopolysaccharide (LPS) (agonist of TLR-4) were used for the combined hyperthermia therapy. The results showed that compared with free IR820, AG modification facilitated much enhanced cellular uptake and greatly pronounced tumor targeting ability. The combined therapy exhibited the most remarkable tumor inhibition compared with the single treatments both in vitro and in vivo. These findings verified...Continue Reading

References

Feb 19, 1998·Journal of Vascular and Interventional Radiology : JVIR·S N GoldbergG S Gazelle
Jul 27, 2001·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·A AseaS K Calderwood
Nov 3, 2005·The Journal of Clinical Endocrinology and Metabolism·Carmen F A Eustatia-RuttenJohannes W Smit
Apr 24, 2008·Bioconjugate Chemistry·Andrea MasottiGiancarlo Ortaggi
Nov 11, 2008·Pharmacology & Therapeutics·Vadivel GanapathyPuttur D Prasad
Jan 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Taoyong ChenXuetao Cao
May 21, 2009·Experimental and Molecular Pathology·Abdullah YalcinJason Chesney
Aug 19, 2011·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Wei YangS Nahum Goldberg
Aug 25, 2011·Nature Reviews. Endocrinology·Matti L GildRoderick Clifton-Bligh
Jan 26, 2013·Journal of Photochemistry and Photobiology. B, Biology·Supriya SrinivasanAnthony J McGoron
Jun 12, 2013·Journal of Visceral Surgery·N Christou, M Mathonnet
Aug 21, 2013·International Journal of Clinical Oncology·Tomoyuki MiyagawaJunichi Ogawa
Jan 11, 2014·Critical Reviews in Oncology/hematology·Ozgur Omur, Yusuf Baran
Feb 14, 2015·The Journal of Clinical Endocrinology and Metabolism·Livia LamartinaDavid S Cooper
Jun 10, 2015·World Journal of Surgical Oncology·Shingo ShimadaMitsuo Kusano

❮ Previous
Next ❯

Citations

Dec 21, 2017·International Journal of Molecular Sciences·Adelaide GrecoMarcello Mancini
Jun 14, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Yeying WangJie Lu
Jul 3, 2021·International Journal of Molecular Sciences·Banendu Sunder DashJyh-Ping Chen
Jun 1, 2020·Fitoterapia·Javad Sharifi-RadRaffaele Pezzani

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
confocal microscopy
NMR
electrophoresis
X-ray
ELISA

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis